DK2563122T3 - Kemiske forbindelser - Google Patents

Kemiske forbindelser Download PDF

Info

Publication number
DK2563122T3
DK2563122T3 DK11775513.2T DK11775513T DK2563122T3 DK 2563122 T3 DK2563122 T3 DK 2563122T3 DK 11775513 T DK11775513 T DK 11775513T DK 2563122 T3 DK2563122 T3 DK 2563122T3
Authority
DK
Denmark
Prior art keywords
mmol
phenyl
methyloxy
ethyl
tetrahydro
Prior art date
Application number
DK11775513.2T
Other languages
English (en)
Inventor
Yulin Wu
Christopher Joseph Aquino
Jon Loren Collins
David John Cowan
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44861895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2563122(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of DK2563122T3 publication Critical patent/DK2563122T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
    • C07F9/6539—Five-membered rings
    • C07F9/6541—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)

Claims (20)

1. Forbindelse ifølge Formel I
hvor R1 er H, Cl, Br, N(CFI3)2 eller methoxy; R2 er Fl eller OH; hver R3 uafhængigt er Ci-5-alkyl; X er CH2, C(O) eller CH=CH; Q er Co-6-alkyl; R4 er NR5R5; hvor én R5 er Fl, og den anden er CFI2C02FI, CFI2S03FI, CFI2CFI2S03FI eller CH(R7)C0-i-alkyCO2H. R7 er C0-6-alkylCO2FI, C0-6-alkylOFI, C0-6-alkylSO3FI eller C0-6-alkylPO3FI2
2. Forbindelse ifølge krav 1, hvor R1 er methoxy.
3. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor R2 er Fl.
4. Forbindelse ifølge krav 1-3, hvor X er CH2.
5. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor X er C(O).
6. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor Q er C0-2- alkyl.
7. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor Q er en C0-alkyl (dvs. er fraværende).
8. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor hver R3 uafhængigt er C2_4-alkyl.
9. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor hver R3 uafhængigt er ethyl eller n-butyl.
10. Forbindelse ifølge et hvilket som helst af de foregående krav, hvor R7 er C0-i-alkylC02H eller C0-2-alkylSO3H.
11. Forbindelse ifølge krav 1, hvilken er
12. Forbindelse ifølge krav 1, hvilken er
13. Forbindelse ifølge krav 12, hvor forbindelsen er krystallinsk.
14. Farmaceutisk acceptabelt salt af en forbindelse ifølge et hvilket som helst af de foregående krav.
15. Farmaceutisk sammensætning omfattende en forbindelse eller et salt ifølge krav 1-14.
16. Farmaceutisk sammensætning ifølge krav 15 til anvendelse i behandling eller forebyggelse af en metabolisk forstyrrelse i et menneske.
17. Forbindelse eller salt som defineret i et hvilket som helst af kravene 1-14 til anvendelse i behandling eller forebyggelse af en metabolisk forstyrrelse i et menneske.
18. Anvendelse af en forbindelse eller et salt som til anvendelse ifølge krav 17, hvor den metaboliske forstyrrelse er diabetes mellitus (Type I og Type II) eller fedme.
19. Forbindelse eller salt som defineret i et hvilket som helst af kravene 1-14 til anvendelse i terapi.
20. Anvendelse af en forbindelse eller et salt som defineret i et hvilket som helst af kravene 1-14 i fremstilling af et medikament til behandling eller forebyggelse af en metabolisk forstyrrelse i et menneske.
DK11775513.2T 2010-04-27 2011-04-27 Kemiske forbindelser DK2563122T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32821210P 2010-04-27 2010-04-27
US32922510P 2010-04-29 2010-04-29
PCT/US2011/034024 WO2011137135A1 (en) 2010-04-27 2011-04-27 Chemical compounds

Publications (1)

Publication Number Publication Date
DK2563122T3 true DK2563122T3 (da) 2016-09-05

Family

ID=44861895

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11775513.2T DK2563122T3 (da) 2010-04-27 2011-04-27 Kemiske forbindelser

Country Status (39)

Country Link
US (1) US9040518B2 (da)
EP (1) EP2563122B1 (da)
JP (1) JP5702853B2 (da)
KR (1) KR101769079B1 (da)
CN (1) CN102858159B (da)
AR (1) AR081337A1 (da)
AU (1) AU2011245393B2 (da)
BR (1) BR112012026767B1 (da)
CA (1) CA2795543C (da)
CL (1) CL2012003009A1 (da)
CO (1) CO6612267A2 (da)
CR (1) CR20120557A (da)
CY (1) CY1118187T1 (da)
DK (1) DK2563122T3 (da)
DO (1) DOP2012000263A (da)
EA (1) EA021753B1 (da)
ES (1) ES2588743T3 (da)
HK (1) HK1175650A1 (da)
HR (1) HRP20161103T1 (da)
HU (1) HUE029480T2 (da)
IL (1) IL222365A (da)
JO (1) JO3131B1 (da)
LT (1) LT2563122T (da)
MA (1) MA34235B1 (da)
ME (1) ME02490B (da)
MX (1) MX2012012527A (da)
MY (1) MY162933A (da)
NZ (1) NZ602754A (da)
PE (1) PE20130384A1 (da)
PL (1) PL2563122T3 (da)
PT (1) PT2563122T (da)
RS (1) RS55079B1 (da)
SG (1) SG184812A1 (da)
SI (1) SI2563122T1 (da)
SM (1) SMT201600293B (da)
UA (1) UA110338C2 (da)
UY (1) UY33353A (da)
WO (1) WO2011137135A1 (da)
ZA (1) ZA201207858B (da)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130225511A1 (en) 2010-11-08 2013-08-29 Per-Göran Gillberg Ibat inhibitors for the treatment of liver diseases
KR20140067070A (ko) * 2011-08-31 2014-06-03 말린크로트 엘엘씨 Ｈ-포스포네이트에 의한 나노입자 ｐｅｇ 개질
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
WO2014178018A1 (en) 2013-05-02 2014-11-06 Glaxosmithkline Intellectual Property Development Limited Therapeutic peptides
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
ES2682171T3 (es) * 2014-08-05 2018-09-19 Glaxosmithkline Intellectual Property (No. 2) Limited Síntesis de benzodiazepinas
KR101674806B1 (ko) * 2014-10-20 2016-11-10 씨제이헬스케어 주식회사 신규한 아미노알킬벤조티아제핀 유도체 및 이의 용도
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10183934B2 (en) 2015-02-02 2019-01-22 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as HDAC inhibitors
WO2016126724A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
WO2017218950A1 (en) 2016-06-17 2017-12-21 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors
WO2018002827A1 (en) * 2016-06-27 2018-01-04 Glaxosmithkline Intellectual Property (No.2) Limited Synthetic methods
JP2020530448A (ja) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ コレスチラミン顆粒、経口コレスチラミン製剤、及びそれらの使用
ES2942443T3 (es) * 2018-06-05 2023-06-01 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores de ácidos biliares
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
JOP20200297A1 (ar) 2018-06-20 2020-11-22 Albireo Ab تعديلات بلورية للأوديفيكسيبات
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
JP2022519370A (ja) 2019-02-06 2022-03-23 アルビレオ・アクチボラグ ベンゾチアジアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
CN113453753A (zh) 2019-02-06 2021-09-28 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
MX2021009622A (es) * 2019-02-12 2021-11-04 Mirum Pharmaceuticals Inc Metodos para tratar la colestasis.
JP2023504647A (ja) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
TW202134221A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
WO2021110884A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202134218A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
PE20230234A1 (es) 2019-12-04 2023-02-07 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del acido biliar
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4232043A1 (en) 2020-10-20 2023-08-30 GlaxoSmithKline Intellectual Property (No.2) Limited Methods for treating cholestatic pruritus
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
WO2022117778A1 (en) 2020-12-04 2022-06-09 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4267558A1 (en) 2020-12-23 2023-11-01 GlaxoSmithKline Intellectual Property (No.2) Limited Forms of linerixibat
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
US20230338392A1 (en) 2022-04-22 2023-10-26 Albireo Ab Subcutaneous administration of an asbt inhibitor
WO2023237728A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
WO2024008766A1 (en) 2022-07-05 2024-01-11 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2370015A (en) 1933-07-24 1945-02-20 Merck & Co Inc Derivatives of tertiary amino aliphatic acids
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
US6268392B1 (en) * 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US20020183307A1 (en) 2000-07-26 2002-12-05 Tremont Samuel J. Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
WO2002053548A1 (en) * 2000-12-27 2002-07-11 Banyu Pharmaceutical Co.,Ltd. Benzothiazepine derivatives
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US20040077625A1 (en) 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
JP2005521653A (ja) * 2002-01-17 2005-07-21 ファルマシア コーポレイション 先端ナトリウム同時依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取込みの阻害剤としての新規アルキル／アリールヒドロキシまたはケトチエピン化合物
JP2006517415A (ja) 2003-01-09 2006-07-27 ジェネンテック・インコーポレーテッド ポリペプチドの精製
GB0304194D0 (en) * 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
WO2006026754A2 (en) 2004-09-03 2006-03-09 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
CA2744817C (en) * 2008-11-26 2020-07-07 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes

Also Published As

Publication number Publication date
BR112012026767A2 (pt) 2015-09-29
CL2012003009A1 (es) 2013-03-08
CO6612267A2 (es) 2013-02-01
SMT201600293B (it) 2016-11-10
UY33353A (es) 2011-12-01
DOP2012000263A (es) 2013-09-15
ME02490B (me) 2017-02-20
ZA201207858B (en) 2014-03-26
MA34235B1 (fr) 2013-05-02
SI2563122T1 (sl) 2016-10-28
PT2563122T (pt) 2016-09-01
EA201290909A1 (ru) 2013-05-30
RS55079B1 (sr) 2016-12-30
AU2011245393B2 (en) 2014-01-23
SG184812A1 (en) 2012-11-29
US9040518B2 (en) 2015-05-26
EA021753B1 (ru) 2015-08-31
CY1118187T1 (el) 2017-06-28
IL222365A (en) 2016-03-31
JP2013525444A (ja) 2013-06-20
CN102858159B (zh) 2015-02-11
MX2012012527A (es) 2012-12-17
WO2011137135A1 (en) 2011-11-03
US20130029938A1 (en) 2013-01-31
HUE029480T2 (en) 2017-02-28
BR112012026767B1 (pt) 2020-01-21
EP2563122B1 (en) 2016-06-08
KR20130060201A (ko) 2013-06-07
PL2563122T3 (pl) 2016-12-30
PE20130384A1 (es) 2013-04-04
LT2563122T (lt) 2016-10-10
MY162933A (en) 2017-07-31
JP5702853B2 (ja) 2015-04-15
HK1175650A1 (zh) 2013-07-12
KR101769079B1 (ko) 2017-08-30
CA2795543A1 (en) 2011-11-03
JO3131B1 (ar) 2017-09-20
NZ602754A (en) 2014-05-30
CN102858159A (zh) 2013-01-02
EP2563122A1 (en) 2013-03-06
HRP20161103T1 (hr) 2016-11-04
AR081337A1 (es) 2012-08-08
ES2588743T3 (es) 2016-11-04
CR20120557A (es) 2013-02-20
CA2795543C (en) 2017-11-28
EP2563122A4 (en) 2013-09-11
UA110338C2 (en) 2015-12-25
IL222365A0 (en) 2012-12-31

Similar Documents

Publication Publication Date Title
DK2563122T3 (da) Kemiske forbindelser
AU2011245393A1 (en) Chemical compounds
CN101784535A (zh) 作为s1p1受体激动剂的新的二羧酸衍生物
CN101296914B (zh) 具有ppar激动活性的衍生物
US7365207B2 (en) Process for the production of chiral propionic acid derivatives
JP6118340B2 (ja) １１−β−ヒドロキシステロイドデヒドロゲナーゼ阻害剤としての環状アミド誘導体およびその使用
AU2013312587A1 (en) Imidazoline derivatives, preparation methods thereof, and their applications in medicine
JPH11500102A (ja) 低脂血症性ベンゾチアゼピン
EP2046766A1 (en) Agonists of the sphingosine- 1- phosphate receptor (slp)
TW201018663A (en) Fluorene compound and pharmaceutical use thereof
CN107001281A (zh) 取代的苯并噻吩基衍生物作为用于治疗ii型糖尿病的gpr40激动剂
JP2005526024A (ja) インスリン分泌を阻害するための化合物及びそれに関連する方法
EP2794607B1 (en) Derivatives of aza adamantane and uses thereof
AU2018359224B2 (en) Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof
KR100254085B1 (ko) 이미다졸릴 메틸-피리딘류 화합물
CN110759914A (zh) 一种治疗糖尿病的药物的制备方法
TWI835325B (zh) (s)-4-氯-2-胺基丁酸鹽酸鹽及(s)-4-氯-2-胺基丁酸酯的製備方法
CN101747253B (zh) 三取代的手性内酰胺类衍生物及其制备方法和用途
EP4370206A1 (en) Esters of 7-cooh cbd derivatives and their use as prevention, prophylaxis of progression, and/or treatment of neurogenerative diseases
TW202321190A (zh) (s)-4-氯-2-胺基丁酸鹽酸鹽及(s)-4-氯-2-胺基丁酸酯的製備方法
WO2001032639A1 (en) Nonpeptide substituted benzothiazepines as vasopressin antagonists
CN117945945A (zh) 一种gpr139受体激动剂、其制备方法及其应用
WO1991017973A1 (en) 5H-DIBENZO(a,d)CYCLOHEPTENES AS MUSCARINIC RECEPTOR ANTAGONISTS
AU681655B2 (en) Serine derivative
EP0980368A1 (fr) Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4